Search clinical trials for: E7389 liposomal formulation

Total 4740 results

Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Eisai Co., Ltd.

Active, not recruiting

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Solid Tumor

Japan
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Breast Cancer

United States
Eisai Inc.

Completed

Study of E7389 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Co., Ltd.
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Solid Neoplasms

Japan
Eisai Co., Ltd.

Completed

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (HAL03T)

Sarcoma, Soft Tissue

Japan
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Limited

Completed

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

Tumor

Netherlands
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Eisai Inc.

Completed

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Cancer

United States, Austria, India
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Eisai Korea Inc.

Completed

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Locally Advanced or Metastatic Breast Cancer

Korea, Republic of
Eisai Co., Ltd.

Completed

Phase I Clinical Study of E7389

Cancer

Japan
Eisai Inc.

Completed

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands
Eisai Inc.

Completed

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

France, Germany, Belgium, Denmark, Poland
Eisai Inc.

Completed

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Suspended

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Eisai Inc.

Completed

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Breast Cancer | Estrogen Receptor Positive Tumor

United States
Eisai Inc.

Completed

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Triple-negative Breast Carcinoma | Progesterone Receptor-negative

United States
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine
University of California, San Francisco
Eisai Inc.

Completed

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Malignant Solid Tumour | Breast Cancer Nos Metastatic Recurrent | Neuropathy

United States
University of Washington
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

Recurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer

United States
Eisai Co., Ltd.

Completed

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Breast Cancer

Japan
University Hospital Muenster
Basilea Pharmaceutica International Ltd

Terminated

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus (AliCLE)

Lupus Erythematosus, Cutaneous

Germany
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
Eisai Inc.

Completed

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

Cancer

United States
Eisai Inc.

Completed

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Non-Small-Cell Lung Carcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Breast Inflammatory Carcinoma | Recurrent Breast Inflammatory Carcinoma | Stage IV Breast Inflammatory Carcinoma

United States
Dana-Farber Cancer Institute

Completed

Eribulin in HER2 Negative Metastatic BrCa

Breast Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Eisai Inc.

Active, not recruiting

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Malignant Solid Neoplasm | Liposarcoma | Malignant Abdominal Neoplasm | Malignant Retroperitoneal Neoplasm | Malignant Scrotal Neoplasm | Malignant Spermatic Cord Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI); Eisai Inc.

Completed

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Primary Brain Tumor | Metastatic Malignant Neoplasm in the Adult Brain

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Recurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical Cancer

United States
University of Baghdad

Unknown

Effect of Topical Melatonin Application on Dental Implant Osseointegration and Marginal Bone Level

Alveolar Bone Loss

Iraq
Hope Rugo, MD
Susan G. Komen Breast Cancer Foundation; Plexxikon

Completed

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma

United States, Canada
Eisai Inc.
Eisai Limited

Completed

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Russian Federation, Italy, Belgium, Canada, South Africa, France, United States, Switzerland, Argentina, Australia, Austria, Brazil, Croatia, Czechia, Hungary, Poland, Spain
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Uterine Corpus Cancer AJCC v7 | Adult Solid Neoplasm

Canada
National Cancer Institute (NCI)

Completed

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

Canada
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Ovarian Cancer | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Eisai Inc.

Completed

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Prostate Cancer

United States
Eisai Inc.
Eisai Limited

Completed

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Breast Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eisai Inc.

Completed

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Breast Neoplasms

United States
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
National Cancer Institute (NCI)

Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States

Search clinical trials for: E7389 liposomal formulation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations